Andexanet alfa vs standard of care for factor Xa inhibitor-induced intracranial hemorrhage-a systematic review and meta-analysis.

ABSTRACT:

Background

Direct oral anticoagulants are activated factor (F)X (FXa) or thrombin inhibitors. Patients on FXa inhibitors are at increased risk for major bleeding events that require anticoagulation reversal. Andexanet alfa is a FXa inhibitor reversal agent, potentially offering better efficacy compared to standard of care options.

Objectives

To conduct a systematic review and meta-analysis comparing the efficacy and safety of andexanet alfa vs standard of care for reversing FXa inhibitor-induced intracranial hemorrhage.

Methods

Random-effects meta-analysis. Ovid Medline, EMBASE, and CINAHL were searched from inception until February 1, 2025. Primary outcomes included hemostatic efficacy, thrombotic events, and mortality. Subgroup analyses isolated studies using 4-fact

SUBMITTER: Xiang AJ 

PROVIDER: S-EPMC12594910 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature